First hearing on the House leadership’s drug price “negotiation” proposal suggests that the real goal of the plan may be to shape negotiations over drug pricing bills – not to create an international price benchmark.
A funny thing happened during the opening statements at the 25 September hearing on the House Democratic leadership’s price “negotiation” bill: an actual conversation broke out among key legislators.
It was primarily a dialogue between House Energy & Commerce/Health Subcommittee Chair Anna Eshoo, D-CA, and full E&C committee ranking...
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
